Ribociclib showed remarkable preclinical efficacy as well as acceptable safety profile and preliminary signs of clinical activity in variety of solid tumors, including HR-positive BC.31–33 Therefore, several trials investigated ribociclib in ER+/HER2- mBC. This evidence concerns the gene ESR1 and breast cancer.